Vincent David1, Thomas P Durkin, Pierre Cazala. 1. Laboratoire de Neurosciences Cognitives, CNRS UMR 5106, Université de Bordeaux I, Avenue des facultés, 33405 Talence Cedex, France.
Abstract
RATIONALE: The involvement of dopamine neurotransmission in opiate reward remains controversial. OBJECTIVE: To investigate the dopaminergic basis of opiate reward by comparing the effect of systemic injection of the D2/D3 antagonist sulpiride on morphine self-administration (ICSA) into the ventral tegmental area (VTA) or the nucleus accumbens (NAc) METHODS: BALB/c mice were unilaterally implanted with a guide cannula 1.5 mm above either the VTA or the NAc. On experimental days, a stainless-steel injection cannula was inserted via the guide cannula, and mice were trained to discriminate the arm of a Y-maze reinforced by intracranial morphine microinjections (6.5 pmol or 65 pmol/50 nl) from the neutral arm (no injection). Following acquisition of morphine ICSA, the dopamine D2/D3 receptor antagonist sulpiride (50 mg/kg, i.p.) was administered 30 min before testing. RESULTS: Sulpiride produced an extinction of intra-VTA, but not intra-NAC, morphine self-administration. Extinction in VTA subjects was followed by a re-appearance of ICSA, although mice continued to receive sulpiride injections. Extinction was re-induced when the dose of sulpiride was raised to 100 mg/kg, whereas no effect of this dose was detected on intra-NAc self-administration. CONCLUSION: Maintenance of intra-VTA, but not intra-NAc, morphine self-administration depends acutely on D2/D3 receptors. However, the deleterious effect of sulpiride on intra-VTA morphine self-administration is transient. Reappearance of ICSA under neuroleptic treatment in VTA subjects may be related to the sensitization effect of intra-VTA morphine infusions, combined with an upregulation of D2/D3 receptors and alterations of DA metabolism by repeated sulpiride injections.
RATIONALE: The involvement of dopamine neurotransmission in opiate reward remains controversial. OBJECTIVE: To investigate the dopaminergic basis of opiate reward by comparing the effect of systemic injection of the D2/D3 antagonist sulpiride on morphine self-administration (ICSA) into the ventral tegmental area (VTA) or the nucleus accumbens (NAc) METHODS: BALB/c mice were unilaterally implanted with a guide cannula 1.5 mm above either the VTA or the NAc. On experimental days, a stainless-steel injection cannula was inserted via the guide cannula, and mice were trained to discriminate the arm of a Y-maze reinforced by intracranial morphine microinjections (6.5 pmol or 65 pmol/50 nl) from the neutral arm (no injection). Following acquisition of morphine ICSA, the dopamineD2/D3 receptor antagonist sulpiride (50 mg/kg, i.p.) was administered 30 min before testing. RESULTS:Sulpiride produced an extinction of intra-VTA, but not intra-NAC, morphine self-administration. Extinction in VTA subjects was followed by a re-appearance of ICSA, although mice continued to receive sulpiride injections. Extinction was re-induced when the dose of sulpiride was raised to 100 mg/kg, whereas no effect of this dose was detected on intra-NAc self-administration. CONCLUSION: Maintenance of intra-VTA, but not intra-NAc, morphine self-administration depends acutely on D2/D3 receptors. However, the deleterious effect of sulpiride on intra-VTA morphine self-administration is transient. Reappearance of ICSA under neuroleptic treatment in VTA subjects may be related to the sensitization effect of intra-VTA morphine infusions, combined with an upregulation of D2/D3 receptors and alterations of DA metabolism by repeated sulpiride injections.
Authors: Thomas C Jhou; Sheng-Ping Xu; Mary R Lee; Courtney L Gallen; Satoshi Ikemoto Journal: Psychopharmacology (Berl) Date: 2012-06-06 Impact factor: 4.530
Authors: M Besson; V David; S Suarez; A Cormier; P Cazala; J-P Changeux; S Granon Journal: Psychopharmacology (Berl) Date: 2006-06-03 Impact factor: 4.530
Authors: Maria C Schippers; Rob Binnekade; Anton N M Schoffelmeer; Tommy Pattij; Taco J De Vries Journal: Psychopharmacology (Berl) Date: 2011-09-02 Impact factor: 4.530
Authors: G I Elmer; J O Pieper; J Levy; M Rubinstein; M J Low; D K Grandy; R A Wise Journal: Psychopharmacology (Berl) Date: 2005-09-29 Impact factor: 4.530